Gevorderde kankerbehandelingsoplossings
"Ons verbind gevorderde stadium kankerpasiënte aan deurbraak selterapieë en kliniese proewe."
"Ons verbind gevorderde stadium kankerpasiënte aan deurbraak selterapieë en kliniese proewe."
“Deur innoverende oplossings en onwrikbare toewyding streef ons daarna om hindernisse uit te skakel, hoop te verskaf, en
dra by tot 'n wêreld waar kanker nie net behandelbaar is nie, maar oorwinbaar is."
CancerFax is 'n baanbrekersplatform wat toegewy is om individue wat kanker in die gevorderde stadium in die gesig staar te verbind met baanbrekende selterapieë soos CAR T-Cell-terapie, TIL-terapie en kliniese proewe wêreldwyd. Hierdie lewensreddende diens bemagtig pasiënte om nuwe grense in kankerbehandeling te verken, terwyl hulle omvattende inligting verskaf oor proefkwalifikasiekriteria, liggings en inskrywingsprosesse.
CancerFax is die mees betroubare internasionale pasiënt fasiliteerder, wat saam met top kanker hospitale in die wêreld soos MD Anderson, Dana Farber, Mayo Clinic, Parkway Singapore, Asan, Sheba, NCC Japan, Beijing Cancer Institute, Apollo, en BLK Max werk om jou die nuutste medisyne en terapieë. Ons span verseker dat pasiënte portierdienste kry vir kankerbehandeling in die VSA, Japan, Suid-Korea, Israel, China en Indië.
Ons maatskappy spesialiseer in kliniese proefdienste vir kanker, wat toegang tot baanbrekende navorsing en behandelingsopsies vergemaklik. Ons verbind pasiënte met die nuutste proewe, wat hoop en vordering in die stryd teen kanker bevorder. Met 'n verbintenis om lewens te verbeter, is ons aan die voorpunt van die bevordering van kankersorg deur kliniese innovasie.
CancerFax spesialiseer in die leiding van individue deur die komplekse proses om in te skryf vir kanker kliniese proewe. Met onwrikbare toewyding verbind ons pasiënte met voorpuntnavorsing en behandelingsopsies, wat 'n reddingsboei van hoop bied in hul stryd teen kanker. Ons span deernisvolle kundiges navigeer deur die ingewikkelde wêreld van kliniese proewe, om te verseker dat elke pasiënt persoonlike ondersteuning en leiding ontvang. Ons is daartoe verbind om pasiënte te bemagtig, hulle toegang tot innoverende terapieë te gee en die stryd teen kanker te bevorder. By ons maatskappy glo ons dat deelname aan kliniese proewe 'n noodsaaklike stap na 'n beter toekoms kan wees.
Gaan besonderhede na
CAR T-selterapie is a revolutionary immunotherapy approach that offers new hope in the fight against cancer. CAR, which stands for Chimeric Antigen Receptor, is a synthetic receptor engineered into a patient’s T cells, the body’s natural defense against diseases. These modified CAR T cells are designed to recognize and attack specific cancer cells with precision, sparing healthy tissues. CAR T cell therapy has shown remarkable success, particularly in treating certain types of leukemia and lymphoma, leading to remissions and improved survival rates in some cases. Despite challenges such as potential side effects and high costs, ongoing research aims to expand its application to a broader range of cancers, promising a brighter future in the battle against this formidable disease.
Gaan besonderhede na
In die VSA is die nuutste kankersorg 'n wonderlike sintese van innovasie, navorsing en allesomvattende sorg. Top kanker hospitale in die VSA use cutting-edge technology like immunotherapy and precision medicine to customize therapies for each patient’s particular genetic composition and cancer type. This tailored strategy has produced better results and fewer negative effects. Clinical trials are also easily accessible, giving patients access to innovative treatments that show promise for the future. However, the high expense of cancer treatment continues to be a problem, sparking continuous discussions about access to and affordability of healthcare. Cancer patients and their families continue to have hope because to the USA’s dedication to breaking new ground in cancer therapy.
Gaan besonderhede na
Kankerbehandeling in Indië het aansienlike vordering gemaak deur gevorderde terapieë soos chirurgie, chemoterapie, bestraling en immunoterapie aan te bied. Top kanker hospitale in Indië like Tata Memorial Centre, Apollo Cancer Hospital, BLK, Artemis, Asian Oncology, American Oncology, HCG, etc., provide world-class care. India’s advantage lies in affordability, attracting medical tourists seeking high-quality, cost-effective cancer treatments.
Gaan besonderhede na
Cancer treatment in Singapore is characterized by cutting-edge medical technology and a holistic approach to care. World-class facilities like the Parkway Cancer Center provide a comprehensive range of treatments, from surgery and chemotherapy to targeted therapies and immunotherapy. Multidisciplinary teams of experienced oncologists tailor personalized treatment plans, ensuring the best outcomes for patients. Singapore’s healthcare system is known for its efficiency and accessibility, attracting patients from around the world. Beyond medical care, the country offers a supportive environment for patients and their families, with numerous support groups and counseling services to help navigate the challenging journey of cancer treatment.
Gaan besonderhede na
Cancer treatment in South Korea is characterized by a harmonious blend of traditional and modern approaches to healthcare. Leading medical institutions like the National Cancer Center Korea and Asan Medical Center offer state-of-the-art technology and a holistic patient-centric approach. South Korea’s healthcare system is renowned for its efficiency, accessibility, and quality of care, attracting patients from across the globe. The country boasts a thriving medical tourism industry, offering advanced treatments such as precision medicine and immunotherapy. Patients benefit not only from cutting-edge therapies but also from a supportive ecosystem of research, clinical trials, and comprehensive cancer care services.
Gaan besonderhede na
Cancer treatment in Israel stands at the forefront of medical innovation. Renowned for its advanced research and pioneering therapies, Israel’s healthcare system offers world-class oncology care. Leading institutions like Sheba Medical Center and Hadassah Hospital leverage state-of-the-art technology, precision medicine, and immunotherapy to combat cancer effectively. Israel’s collaborative environment encourages groundbreaking research and clinical trials, making it a hub for innovation in oncology. Additionally, a compassionate and multidisciplinary approach ensures holistic patient care, while medical tourists seek its expertise. Israel’s commitment to cancer treatment extends beyond borders, offering hope and advanced solutions to patients worldwide.
India’s innovative CAR-T cell therapy, NexCAR19, is the country’s initial indigenous strategy to fight cancer. Created by ImmunoACT, a branch of IIT Bombay, this advanced therapy utilizes genetically modified T-cells to target and eliminate cancerous cells, specifically in blood malignancies such as leukemia and lymphomas. Initial trials demonstrate potential, with around 50% obtaining total remission, particularly in juvenile cases of B-cell acute lymphoblastic leukemia. NexCAR19 shows decreased neurotoxicity in comparison to foreign options, indicating possible benefits over current treatments. India plans to provide this treatment at a reduced cost compared to worldwide prices, starting at roughly INR 30–40 lakhs and aiming to lower it to INR 10–20 lakhs with regulatory approval.
Gaan besonderhede na
CAR T-selterapie in China has seen remarkable advancements in recent years, mirroring the global progress in this cutting-edge cancer treatment. With more than 700 ongoing clinical trials, China leads the development of CAR T-Cell therapy. China has swiftly embraced CAR T-cell therapy, offering new hope to patients battling various cancers, including leukemia and lymphoma. Several Chinese hospitals and research institutions are actively conducting clinical trials and providing CAR T-cell therapy to eligible patients. The country’s robust infrastructure and access to a vast patient population have accelerated research and development efforts. With a commitment to advancing this innovative therapy, China is significantly contributing to the global landscape of cancer immunotherapy, enhancing treatment options for patients nationwide.
Gaan besonderhede na
In Israel, CAR T-cell therapy has emerged as a transformative approach in the fight against cancer. The country’s healthcare sector, known for its world-class research and innovation, has made significant strides in developing and implementing CAR T-cell therapies for patients with hematologic malignancies and solid tumors. Leading medical institutions and biotechnology companies in Israel are actively involved in clinical trials and research projects, pushing the boundaries of CAR T-cell therapy. Israel’s collaborative environment and cutting-edge technologies have positioned it as a global player in advancing immunotherapy, offering new treatment avenues and hope for cancer patients, both domestically and worldwide.
Gaan besonderhede na
CAR T-cell therapy has made significant inroads in Singapore’s healthcare landscape, offering a promising avenue for cancer treatment. The country’s advanced medical infrastructure and research capabilities have enabled the development and application of this cutting-edge immunotherapy. Patients in Singapore now have access to CAR T-cell therapy for various blood cancers, marking a transformative shift in oncology care. Local healthcare institutions are actively involved in clinical trials and collaborations with global experts, ensuring patients receive world-class treatment. With its commitment to innovation and patient-centric care, Singapore is playing a pivotal role in advancing CAR T-cell therapy, providing new hope to cancer patients in the region and beyond.
Gaan besonderhede na
"Ons visie is om die pad te lei in die rewolusie van kankerbehandelingfasilitering, om elke individu se toegang tot pasgemaakte, omvattende en deernisvolle sorg te verseker. Deur innoverende oplossings en onwrikbare toewyding streef ons daarna om hindernisse uit te skakel, hoop te verskaf en by te dra tot 'n wêreld waar kanker nie net behandelbaar is nie, maar oorwinbaar is."
"Op KankerFaks, ons missie is om die brug te wees tussen individue wat kanker sukkel en die gevorderde behandelings wat hulle verdien.”
"Deur onwrikbare toewyding, innovasie en 'n deernisvolle gees, streef ons daarna om die kankerbehandelingslandskap te herdefinieer, en bied hoop, genesing en 'n beter toekoms vir almal wat deur kanker geraak word."
Gaan besonderhede na
Ons is lief vir ons gebruikers omdat hulle van ons hou. Kyk bietjie van die liefde wat hulle na ons kant toe gestuur het
“I am writing this testimonial to express my profound gratitude for the life-changing experience I had with the CancerFax team, who introduced me to CAR T-cell therapy in China. My journey battling cancer took a hopeful turn when I was introduced to this groundbreaking treatment, and it has been nothing short of remarkable. Before CAR T-cell therapy, I had exhausted conventional treatments without much success. My situation was dire, and hope was fading. However, my decision to undergo CAR T-cell therapy in China was a turning point. The level of care and expertise I received was exceptional. The medical team was not only highly skilled but also incredibly compassionate, providing me with the support and reassurance I needed during this challenging time.”
Veelvuldige myeloom-oorlewende, Noorweë
Vind hieronder die antwoorde op die mees algemene vrae wat pasiënte oor kankerbehandeling het.
Gevorderde kankerbehandelingsopsies sluit in:
Immunoterapie: Hierdie behandeling gebruik die liggaam se immuunstelsel om kankerselle te beveg. Dit kan hoogs effektief wees in sekere kankers deur die immuunrespons teen kankerselle te versterk.
Doelgerigte terapie: Dit behels middels wat spesifiek genetiese mutasies of abnormaliteite binne kankerselle teiken, wat skade aan gesonde selle tot die minimum beperk.
Presisie medisyne: Deur 'n pasiënt se genetiese samestelling en tumoreienskappe te ontleed, kan dokters behandelings vir spesifieke kankertipes aanpas, wat lei tot meer effektiewe uitkomste.
MOTOR T-sel terapie: Hierdie innoverende terapie behels die genetiese modifikasie van 'n pasiënt se T-selle om kankerselle te herken en aan te val, veral in bloedkankers soos leukemie, veelvuldige myeloom en limfoom.
Gevorderde kankerbehandelings bied verskeie voordele:
Verbeterde doeltreffendheid: Geteikende terapieë en immunoterapieë is dikwels meer effektief en presies, wat lei tot beter uitkomste en minder newe-effekte.
Persoonlike benadering: Gevorderde behandelings word dikwels aangepas by 'n individu se genetiese en molekulêre profiel, wat die doeltreffendheid maksimeer terwyl onnodige behandeling tot die minimum beperk word.
Verminderde newe-effekte: In vergelyking met tradisionele chemoterapie en bestraling, kan gevorderde terapieë minder ernstige newe-effekte hê, wat lewenskwaliteit tydens behandeling verbeter.
Verhoogde oorlewingsyfers: Baie gevorderde behandelings het getoon om oorlewingsyfers en langtermyn-uitkomste aansienlik te verbeter, veral in gevalle van gevorderde of metastatiese kanker.
Toegang tot gevorderde kankerbehandelings behels verskeie stappe:
KankerFaks: Stuur vir ons jou mediese verslae per e-pos of WhatsApp en ons mediese span sal jou lei met die beste beskikbare gevorderde kankerbehandelingsopsies.
Konsultasie met onkoloog: Pasiënte moet gevorderde behandelingsopsies met hul onkoloog bespreek, wat inligting oor beskikbare terapieë en geskiktheid vir individuele gevalle kan verskaf.
Kliniese proewe: Deelname aan kliniese proewe kan toegang bied tot die nuutste behandelings wat nog nie algemeen beskikbaar is nie.
Gesondheidsversekeringsdekking: Pasiënte moet met hul gesondheidsversekeringsverskaffer raadpleeg om dekking vir gevorderde behandelings en gepaardgaande koste te verstaan.
Verwysing na gespesialiseerde sentrums: Verwysing na gespesialiseerde kankersentrums of hospitale wat bekend is vir gevorderde kankersorg kan toegang tot 'n wyer reeks behandelingsopsies verseker.
Pasiëntvoorspraakgroepe: Hierdie groepe kan hulpbronne, ondersteuning en inligting verskaf oor toegang tot gevorderde behandelings en om die gesondheidsorgstelsel effektief te navigeer. Sluit aan by ons Facebook-groep, Oorwin kanker.
KankerFaks is verbonde aan sommige van die wêreld en die VSA se top kankerhospitale. Kyk na ons lys hospitale hierbo en kies die een wat aan u vereistes voldoen. Ons mediese span kan jou ook help om die een te kies wat by jou vereistes en behoeftes pas. Kyk na die lys van die beste kankerhospitale in die VSA. .
CAR T-sel terapie, of chimeriese antigeen reseptor T-sel terapie, is 'n innoverende immunoterapie benadering. Dit behels die versameling van 'n pasiënt se eie T-selle, die genetiese modifikasie daarvan om kankerselle meer effektief te teiken, en dan die infusie van hierdie gemodifiseerde selle terug in die pasiënt se liggaam. Die CAR T-selle kan kankerselle met presisie herken en aanval. Kyk na die volledige besonderhede oor CAR T-Cell terapie. .
Ja, sommige maatskappye het begin CAR T-selterapie in Indië met behulp van vektore uit China en Maleisië. Hierdie terapie is egter steeds onder kliniese toetse. Pasiënttoestemmingsvorms en dokteradvies word ingewin voordat jy vir hierdie proewe gaan.
In China word CAR T-selterapie hoofsaaklik goedgekeur en gebruik vir die behandeling van hematologiese maligniteite, soos bv. limfoom, leukemie en myeloom.
Alhoewel daar 'n paar kliniese proewe en navorsingspogings is wat CAR T-selterapie vir soliede gewasse ondersoek, was vordering in hierdie area stadiger in vergelyking met hematologiese kwaadaardige siektes.
Volgens die beskikbare inligting maak CAR T-selterapieë vir soliede gewasse slegs 9% uit van die totale CAR T-selterapieë wat in China ontwikkel word.
CAR T-Cell terapie koste in China wissel tussen 45,000 90,000 USD en XNUMX XNUMX USD. Die algehele koste hang af van die hospitaal wat gekies word en die aantal teikenantigeene wat gekies is. Die koste van die goedgekeurde CAR-T-selterapieë in China is oor die algemeen ongeveer 1,200,000 170,000 XNUMX Chinese yuan (CNY), wat gelykstaande is aan ongeveer VS$XNUMX XNUMX. Die koste van Cilta-Cel, FUCASO (NMPA-goedgekeur) vir veelvuldige myeloom wissel tussen 250,000 en 300,000 dollar. Die kostedoeltreffendheid van CAR-T-selterapieë in China wissel na gelang van die spesifieke terapie en die pasiënt se toestand.
ESTD: 1941
Aantal beddens: 1200
Die MD Anderson Cancer Centre is 'n erkende organisasie wat die wêreld lei in kankerbehandeling, navorsing en opvoeding. Dit is in 1941 gestig en is gebaseer in Houston, Texas. Dit is lank reeds 'n leier in kankernavorsing en -behandeling. Die fasiliteit is vernoem na Monroe Dunaway Anderson, 'n ryk sakeman en filantroop wat die idee gehad het om 'n omvattende kankersentrum te bou wat 'n rewolusie sou verander hoe kanker verstaan en behandel word.
ESTD: 2001
Aantal beddens: 380
Parkway Hospitale lok internasionale pasiënte vanweë sy wêreldklas mediese fasiliteite en kundigheid. Parkway Hospitals is Asië se grootste private gesondheidsorgverskaffer.
ESTD: 2003
Aantal beddens: 400
Beijing Gobroad Boren-hospitaal is 'n mediese fasiliteit in private besit wat toegewy is aan gevorderde mediese tegnologie, deernisvolle sorg en pasiënttevredenheid, wat die welsyn van pasiënte bo alles prioritiseer. Ons inkorporeer die gevorderde kennisstelsel, diagnostiese en behandelingsprosedures, volhoubare mediese opleiding, pasiëntopvoeding, hospitaaladministrasie en dienskonsep van die topvlak mediese groep in die Verenigde State, Mayo Clinic.